TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders  by Massagué, Joan et al.
Cell, Vol. 103, 295–309, October 13, 2000, Copyright ª 2000 by Cell Press
TGFb Signaling in Growth Control, Review
Cancer, and Heritable Disorders
receptors funnel their activities through one of two
groups of Smad proteins (Figure 1).
Several key events in the TGFb receptor activation
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Memorial Sloan-Kettering Cancer Center process are now understood. Adjacent to the kinase
domain of the type I receptors is a conserved 30 aminoNew York, New York 10021
acid segment known as the GS region (for a GSGS se-
quence it contains). In the basal state, the GS region
The transforming growth factor b (TGFb) pathway occu- forms a wedge that presses against the catalytic center
(Huse et al., 1999). The immunophilins FKBP12 andpies a central position in the signaling networks that
control the growth, differentiation, and final fate of meta- FKBP12.6 bind to the GS domain and stabilize this inac-
tive conformation. Activation occurs when the type IIzoan cells. Over the past few years, remarkable progress
has been made in identifying the central components receptors phosphorylate the GS domain. To achieve
this, the ligand must bring together type I and type IIof this pathway, defining their interactions, and deci-
phering how a cell interprets its signals. Along the way, receptors, forming a heteromeric complex. The ligands
themselves are dimers (most often homodimers heldgenetic alterations have been discovered in this path-
way that provide answers to long-standing questions together by disulfide bonds), and each monomer has
contact sites for type I and type II receptors, as definedabout the molecular basis of certain common somatic
disorders as well as rare inherited ones. Recent reviews using BMP2 (Kirsch et al., 2000a). The extracellular re-
gion of the receptors is formed by a small, tightly foldedhave covered TGFb signal transduction (Heldin et al.,
1997; Massague´, 1998; Whitman, 1998), transcriptional globular domain (Greenwald et al., 1999; Kirsch et al.,
2000b) and the cytoplasmic region by a short juxtamem-control (Derynck et al., 1998; Massague´ and Wotton,
2000), and the regulation of these processes (Massague´ brane segment, a protein kinase domain, and often little
else (Huse et al., 1999). In several cases, the extracellularand Chen, 2000). The present review focuses on the
control of cell growth and differentiation by the TGFb or cytoplasmic regions contain alternatively spliced ex-
tensions of unknown function (Massague´, 1998, and ref-family, and the human disorders that result from genetic
alterations in these pathways. erences therein). One of these extensions, on the car-
boxy-terminus of the BMP type II receptor BMPR-II,
is the target of mutations that cause familial primaryThe Basics of TGFb Signaling
Nearly thirty members of the TGFb family have been pulmonary hypertension in humans (see below).
described in human, and many orthologs are known in
mouse, Xenopus, and other vertebrates (Hogan, 1996; Smad Transcription Factors
Massague´, 1998). Four are present in Caenorhabditis Smad proteins are the only known TGFb receptor sub-
elegans (Padgett et al., 1998), and seven in Drosophila strates capable of signal transduction. They consist of
melanogaster (Raftery and Sutherland, 1999). The family two conserved globular domains known as the MH1
is divided into two general branches (the BMP/GDF and (Mad homology 1) and MH2 domains coupled by a linker
TGFb/Activin/Nodal branches) whose members have di- region (Figure 3) (Shi et al., 1997, 1998). The MH1 domain
verse, albeit often complementary, effects. Additional recognizes the DNA sequence CAGAC (Kim et al., 1997;
members such as inhibin-a act as ligand antagonists. Shi et al., 1998; Zawel et al., 1998) whereas the MH2
Some family members are expressed only in a few cell domain binds the transcriptional coactivators p300 and
types or for limited periods of time during development, CBP in competition with the corepressors TGIF, Ski, and
whereas others are widespread during embryogenesis SnoN (reviewed in Massague´ and Wotton, 2000).
and in adult tissues. AMH/MIS (Anti-Mu¨llerian hormone Smads 2 and 3 (and perhaps the other Smads as well)
or Mu¨llerian inhibiting substance) and GDF8/myostatin have intrinsic nuclear import activity in the MH2 domain
are examples of the former; TGFb1 and BMP4 of the (Xu et al., 2000a). In the cell, however, most Smads are
latter. kept in the cytoplasm in the basal state, which ensures
TGFb factors initiate signaling by assembling receptor their prompt exposure to activated receptors. Cyto-
complexes that activate Smad transcription factors (Fig- plasmic retention of Smads 2 and 3 is achieved in part by
ure 1) (Massague´, 1998). The ligand brings together binding to the protein SARA (Smad anchor for receptor
members from two families of receptor serine/theonine activation) (Tsukazaki et al., 1998). SARA plays three
kinases, known as the type I and type II receptors. The roles: it tethers Smads in the cytoplasm, it occludes a
only known function of the type II receptors is to activate nuclear import signal on the MH2 domain (Xu et al.,
the type I receptors. The type I receptors propagate the 2000a), and it facilitates Smad presentation to the acti-
signal by phosphorylating the Smads (Figure 1). Each vated receptors (Tsukazaki et al., 1998). Besides the
ligand may have a choice of several type I and/or type Smad binding region, SARA contains a FYVE domain,
II receptors (Figure 2), and a given cell may express a structure that in other proteins mediates binding to
different receptor forms. However, the various type I phosphatidylinositol 3-phosphate on endosome mem-
branes.
The Smads that serve as receptor substrates* To whom correspondence should be addressed (e-mail:
j-massague@ski.mskcc.org). (R-Smads) fall into two groups, each serving one branch
Cell
296
possibility that TGFb may simultaneously activate Smad
and MAP kinase pathways that then physically converge
on target genes (Zhang et al., 1998; Hanafusa et al.,
1999; Sano et al., 1999; Wong et al., 1999). However,
the physiological role of MAP kinases in TGFb signaling
remains uncertain due to a paucity of supportive genetic
evidence.
Decisions in the Nucleus
By placing Smads in the nucleus, TGFb conveys a signalFigure 1. The Basics of TGFb Signaling
but does not provide precise instructions. The cell’sA ligand-induced receptor complex phosphorylates a member of
genetic makeup and responses to other signal inputs,the R-Smad class (Smads1, 2, 3, 5, or 8), enabling its association
more than the Smad complex itself, determine whatwith Smad4 and accumulation in the nucleus. In the nucleus, the
activated Smad complex associates with two classes of proteins: genes will be recognized by this complex and the out-
DNA binding cofactors that will help select target genes, and coacti- come of this target gene selection. This cellular context
vators or corepressors that will determine the transcriptional effect consists of at least two classes of Smad-interacting
on the target genes. Smads have intrinsic nuclear import activity,
molecules: DNA binding cofactors and transcriptionalbut, at least in the case of Smad2/3, these proteins are retained in
coactivators and corepressors.the cytoplasm by binding to SARA. Receptor-mediated phosphory-
Why are DNA binding cofactors needed if Smads canlation of a R-Smad decreases its affinity for SARA and increases its
affinity for Smad4. bind DNA on their own? As it turns out, the affinity of
Smads for their cognate sequence is too low to achieve
unassisted binding to DNA (Shi et al., 1998). Cooperation
of the TGFb family (Figure 2). Structural elements have between R-Smad and Smad4 might suffice for binding to
been identified that determine the specificity of the re- certain genes that have two or more CACAG sequences
ceptor–Smad interaction (Chen et al., 1998a) (Figure 3). appropriately spaced. However, many Smad gene re-
Receptor phosphorylation of R-Smads, which occurs at sponses are dependent on the cell type and conditions,
the the carboxy-terminal end sequence SXS, diminishes implying that cell-specific factors dictate the choice of
the affinity of Smad2 for SARA, exposing the nuclear Smad target genes. Indeed, a group of structurally di-
import signal. At the same time, phosphorylation in- verse proteins is emerging that plays such a role (Whit-
creases the affinity of R-Smads for a second group, man, 1998, and references therein; Massague´ and Wot-
called Co-Smads, that are essential for the assembly of ton, 2000) (Figure 2). These molecules cooperate with
transcriptional complexes (Xu et al., 2000a). Only one activated Smads in binding only to those promoters that
Co-Smad (Smad4) is known in human and mouse, and fulfill the combined sequence specificity requirements
it is shared by all R-Smads (Figure 1). A second Co- of a given Smad-cofactor combination. The expression
Smad (Smad4b) has been identified in Xenopus (Howell of a Smad-DNA binding cofactor may be cell-type spe-
et al., 1999; Masuyama et al., 1999). Smad4 contains a cific, conferring cell type specificity to a Smad response.
nuclear export signal (NES) that keeps it out of the nu- Furthermore, each R-Smad subgroup is competent to
cleus in the absence of agonist stimulation (Watanabe associate with a different subset of DNA binding cofac-
et al., 2000). Smad4b lacks this NES and is constitutively tors, thus achieving pathway specificity (Figure 2). Some
nuclear (Masuyama et al., 1999). Beyond this, the role of Smad DNA binding cofactors, such as the winged-helix/
nuclear export of Smad4 and the functional differences forkhead family member FAST, the homeodomain pro-
between Smad4 and 4b remain unknown. tein Mixer, and the 30 zinc finger protein OAZ, have no
detectable transcriptional activity on their own, whereas
others, including c-Jun, TFE3, and Lef1/TCF, do (De-Alternative Pathways
Smad function is involved in most actions of the TGFb rynck et al., 1998; Germain et al., 2000; Labbe et al.,
2000; Massague´ and Wotton, 2000; Nishita et al., 2000).family, which is not to say that the TGFb receptors could
not act on other substrates and activate other pathways. Several of these are responsive to their own set of extra-
cellular signals. For instance, c-Jun responds to diverseSeveral Smad4-defective cell lines from human or
mouse retain some level of reponsiveness to TGFb, sug- cytokines and cellular stress, and Lef1/TCF responds
to Wnt/b-catenin signals.gesting that, if R-Smads are involved in these responses,
they can do so without Smad4 (Dai et al., 1999; Sirard On DNA, the Smad complex can recruit either tran-
scriptional coactivators or corepressors (Luo et al.,et al., 2000). A series of reports indicate that several MAP
kinases (JNK, p38, and Erk) can be rapidly activated by 1999; Sun et al., 1999; Wotton et al., 1999). Smad
corepressors need not be viewed solely as negativeTGFb in a manner that is highly dependent on the cell
type and conditions. The biochemical link between the regulators of Smad function. In theory at least, Smad
corepressors might also serve as mediators of geneTGFb receptors and MAP kinase pathways has been
elusive, although evidence suggests that the MAPKKK downregulation by TGFb signals. Histone acetyl trans-
ferase activity associated with p300 and CBP and his-family member TAK1 (Takatsu et al., 2000) and Rho pro-
teins (Engel et al., 1999) could be involved in this link. tone deacetylases (HDACs) recruited by TGIF, Ski, and
SnoN give rise to Smad complexes of opposite chroma-At least one TGFb response, fibronectin induction, has
been partly ascribed to JNK activation (Hocevar et al., tin remodeling activity. At a minimum, the choice be-
tween coactivators and corepressors depends on the1999). Smads can interact in vitro with the JNK and
p38 substrates c-Jun and ATF2, respectively, raising the relative abundance of these proteins. TGFb can regulate
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Figure 2. Ligand, Receptor, and Smad Relationships in the TGFb System
Two branches of the Smad pathway mediate signaling by the two main groups of TGFb family agonists. The TGFbs, Activins, and Nodals
(and the Nodal-related Xnr factors from Xenopus) engage receptors that phosphorylate Smads 2 and 3. The BMPs and related GDFs, as well
as AMH/MIS, engage receptors that signal through Smads 1, 5, and 8. Orthologs from Drosophila are listed in red color. Alternative type I
receptor names are: ALK3 (BMPR-IA), ALK4 (ActR-IB), ALK5 (TbR-I) and ALK6 (BMPR-IB). Activins and BMPs share some of their type II
receptors, as indicated. Activated R-Smads share co-Smads but not DNA binding cofactors. Smad4b has been reported only in Xenopus.
The DNA binding cofactors belong to structurally different protein families (see text for details). BMP, bone morphogenetic protein; GDF,
growth and differentiation factor; DPP, decapentaplegic; and AMH/MIS, anti-Mu¨llerian hormone/Mu¨llerian inhibiting substance.
both positively and negatively the levels of Ski and SnoN, Nodal; and follistatin binds activin (Massague´ and Chen,
2000, and references therein). The expression or activitybut little else is known about the regulation of Smad
corepressors and how Smad subunit composition might of these proteins is controlled by various signals such
as Sonic Hedgehog in the case of Caronte, thrombo-influence corepressor recruitment.
sponding in the case of LAP, and BMP itself in the case
of Noggin. In contrast, a group of membrane-anchoredNetworking
proteins function as enhancers of ligand binding to theLigand access to TGFb receptors is so highly controlled
receptors. Via its protein moiety, the proteoglycan be-that the ligand-receptor interaction may be viewed as
taglycan (also known as the TGFb type III receptor) en-the midpoint rather than the start of a TGFb signaling
hances TGFb binding to its signaling receptors (Lo´pez-pathway (reviewed in Massague´ and Chen, 2000). Sev-
Casillas et al., 1993) and enables the activin antagonist,eral structurally diverse soluble proteins have been iden-
inhibin, to bind to activin receptors (Lewis et al., 2000). Atified that bind TGFb factors, preventing their access to
structurally related protein, endoglin, may have a similarmembrane receptors (Figure 4). The pro-peptide from
role for TGFb1 or a hitherto unknown family memberthe TGFb precursor (referred to as “latency-associated
(Arthur et al., 2000). Cripto in mouse and its ortholog inprotein”, LAP) binds TGFb; noggin, chordin, caronte,
cerberus, and others bind BMPs; cerberus also binds zebrafish are putative accessory receptors for Nodal-
Figure 3. Smad Functional Domains and
Cancer Mutations
The MH1 and MH2 domains are conserved in
all R-Smads and co-Smads and form globular
structures. They are linked by a more diver-
gent region. The functions of these three re-
gions are listed. Identification of the DNA
binding site (hairpin) is based on the crystal
structure of the Smad3 MH1 domain bound
to its cognate sequence (Shi et. al, 1998). The
Smad interacting regions in the MH2 domain
are based on the crystal structure of this do-
main in Smad4 (Shi et. al, 1997). The multiple
contact sites with SARA are based on the
crystal structure of a SARA–Smad2 complex (Wu et. al, 2000). Other protein interaction sites have been defined by site-directed mutagenesis.
Tumor-derived mutations are indicated by black bars for Smad4 and red bars for Smad2.
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Figure 4. TGFb Pathway Integration into a
Signaling Network
A signaling network controls the activity of
the TGFb/Smad pathway at multiple levels.
Only a few representative examples are
shown. Noggin, Caronte, and LAP are inhibi-
tors of ligand binding to the signaling recep-
tors. Betaglycan and endoglin are enhancers
of ligand-access to the signaling receptors.
FKBP12 keeps the type I receptors in the
basal state. BAMBI is a truncated receptor-
like protein that inhibits type I receptor activa-
tion. Smurf is an E3 ubiquitin ligase that medi-
ates Smad degradation. Smad7 and Smad6
are decoy Smads that interfere with receptor
interaction with R-Smads or R-Smad interac-
tion with Smad4. Erk MAP kinase phosphory-
lation attenuates nuclear accumulation of the
Smads. TGIF, Ski, and SnoN are Smad tran-
scriptional corepressors. TGIF competes
with the coactivatior p300 for binding to the
Smad complex. The level or activity of several
of these components is controlled by diverse
signals as indicated.
related factors (Schier and Shen, 2000). In humans, nog- and downregulation of c-myc (Figure 5A). In mammalian
cells, cyclin D-cdk4, cyclin D-cdk6, cyclin E-cdk2, andgin mutations cause skeletal defects, and endoglin mu-
cyclin A-cdk2 act sequentially during the G1/S transitiontations cause vasculature malformations (see below),
and are required for cell-cycle progression through thisunderscoring the physiological importance of these ex-
period. Cdk activity is tightly regulated by diverse mech-tracellular regulators.
anisms, including changes in the levels of cyclins orThe Smad signal transduction process itself may be
cdks, phosphorylation of positive and negative regula-simple but it is under the control of a complex web of
tory sites, and interaction with stoichiometric inhibitorsregulators (Figure 4). Several of these molecules, includ-
(Sherr and Roberts, 1999). The early observation thating the truncated receptor-like molecule BAMBI, the
TGFb inhibits phosphorylation of the retinoblastomaubiquitin ligase Smurf1, and the antagonistic Smads,
protein pRb (a cdk substrate) during G1, pointed at G1Smad6 and Smad7, specialize in regulating this path-
cdks as targets of TGFb action and eventually unveiledway. The levels of many of these molecules are con-
various gene responses that may vary among differenttrolled by diverse signals, providing feedback and cross-
cell types but in all cases suppress the activity of G1talk links. Additional control and integration are provided
cdks.by signals that regulate the levels or activity of Smad
DNA binding cofactors, including the aforementioned
Cdk Inhibitory Gene Responses: Many WaysWnt and diverse cytokine signals (reviewed in Massague´
to the Same Endand Chen, 2000). The Smad pathway is therefore well
As first demonstrated in keratinocytes (Hannon andintegrated into the signaling networks of the cell at large.
Beach, 1994), TGFb rapidly induces the expression of
p15Ink4b (henceforth p15) in a variety of different cell
types, including lung, thyroid, and mammary epithelial
Growth Control
cells, and astrocytes (Figure 5A). p15, a member of the
Inhibition of cell proliferation is central to the TGFb re- Ink4 family of cdk inhibitors, specifically inhibits the
sponse in epithelial, endothelial, hematopoietic, neural, cyclin D-dependent kinases, cdk4 and cdk6, by binding
and certain types of mesenchymal cells, and escape to the cdk subunit, inactivating the catalytic activity and
from this response is a hallmark of many cancer cells. preventing the assembly of new cyclin D-cdk complexes
TGFb can induce antiproliferative gene responses at from latent pools. Cyclin D-cdk4/6 complexes function
any point during the division cycle. However, these re- early in G1 and act as mitogen sensors. Their inhibition
sponses are effective at inhibiting cell cycle progression by TGFb via p15 thus deprives the cell of this class of
only during G1. Once a cell becomes committed to exe- G1 cdk activities.
cuting DNA replication in late G1, the division cycle will Cyclin D-cdk4/6 complexes also support cell cycle
proceed undeterred by TGFb until the cell enters G1 progression with a noncatalytic function, namely, the
again following mitosis, at which point the cell cycle will sequestration of the cdk inhibitor p27Kip1 (henceforth
arrest. In most cases this arrest is reversible, but in some p27). This function, too, is targeted by p15 (Reynisdo´ttir
cases, it is associated with terminal differentiation or et al., 1995; Sandhu et al., 1997). Cip/Kip cdk inhibitors,
programmed cell death. including p21Cip1, p27Kip1, and p57Kip2, can interact
Two classes of antiproliferative gene responses are with cyclin D-cdk4/6, cyclin E-cdk2, and cyclin A-cdk2.
involved in TGFb-mediated growth arrest: gene re- This interaction is mediated by two conserved subdo-
mains, one docking on the cyclin subunit and the othersponses that inhibit cyclin-dependent kinases (cdks),
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seen in TGFb-treated cells. However, in HepG2 hepato-
cellular carcinoma cells, TGFb inhibits this phosphoryla-
tion without a detectable change in the levels or associa-
tion of known cdk inhibitors (Nagahara et al., 1999).
Thus, these mechanisms have backups, as illustrated
also by the fact that p152/2 or p272/2 mouse embryo
fibroblasts remain at least partly growth inhibited by
TGFb (Nakayama et al., 1996; Latres et al., 2000). Fur-
thermore, TGFb induces the expression of p21 in kera-
tinocytes, colon, and ovarian epithelial cells (Figure 5A).
TGFb addition can also prevent the increase in cdk4
levels that occurs under the particular conditions of mi-
togen-deprived cell cultures replenished with serum;
this effect occurs at the translational level, requires the
59UTR of cdk4, and is p53 dependent (Ewen et al., 1995).
Another cdk inhibitory response to TGFb is the downreg-
ulation of cdc25A (Iavarone and Massague´, 1997) (Fig-
ure 5A). The cdc25 family of tyrosine phosphatases re-
moves inhibitory tyrosine phosphorylation from cdks.
Cdc25A downregulation by TGFb in MCF-10A mammary
epithelial cells leads to accumulation of tyrosine phos-
phorylation on cdk4 and cdk6 and subsequent inhibition
of these kinases. A mutant form of cdk6 lacking the
phosphorylatable tyrosine residue is resistant to inhibi-
tion by TGFb in these cells. This multiplicity of antiprolif-
erative TGFb gene responses assures that growth inhibi-Figure 5. The Cell Cycle Arrest Response to TGFb
tion will generally be achieved in nontransformed cells.(A) Two classes of antiproliferative gene responses are known to
TGFb also downregulates cdc25A in keratinocytes (Ia-be induced by TGFb. The first is c-Myc downregulation, observed
varone and Massague´, 1999). In these cells, however,in most cell types that are growth inhibited by TGFb. The second
are cdk-inhibitory responses, including the induction of p15 and cdc25A downregulation is a secondary event following
p21 and the downregulation of cdc25A. Most cells that are growth the initial drop in cdk kinase activity caused by the cdk
inhibited by TGFb have different combinations of cdk-inhibitory re- inhibitors, p15 and p21. TGFb-induced cdc25A down-
sponses. c-Myc antagonizes TGFb signaling by acting as a repres- regulation involves formation of a transcriptional repres-
sor of cdk-inhibitory responses. Downregulation of c-Myc is thus
sor complex containing E2F, the pRb-related proteinnecessary for TGFb-induced cell cycle arrest. Loss of cdc25A and
p130, and the histone deacetylase HDAC1. Binding ofthe induction of p21 or p15 lead to the direct inhibition of cyclin
this complex to an E2F site in the cdc25A promoterD-cdk4.
(B) p15 binding to cyclin D-cdk4 leads to the shuttling of p27 from represses expression of this gene. This type of response
active cyclin D-cdk4-p27 complexes to cyclin E-cdk2 complexes, may be representative of the large number of adaptive
resulting in their ultimate inhibition as well. changes in gene expression that follow the entry of a
cell into a quiescent state. Other TGFb-induced changes
in cell cycle components that occur with slow kinetics
contacting the associated cdk subunit (Pavletich, 1999). (i.e., several hours after TGFb addition), such as the
Through these contacts, p27 acts as an inhibitor of downregulation of various cyclins and cdk’s (Geng and
cyclin E/A-cdk2 complexes but it is not an obligate inhib- Weinberg, 1993; Reynisdo´ttir et al., 1995), may fall in
itor of cyclin D-cdk4/6, In fact, p27 and p21 have been this category. Transcript profiling of mammary epithelial
proposed to facilitate the assembly of cyclin D-cdk com- cells using DNA microarrays indicates that the levels of
plexes. Most of the p27 protein in a proliferating cell is nearly 1% of all transcripts in the cell change several
found in association with cyclin D-cdk4/6, thus sparing fold after four hours of TGFb addition (J. M., unpublished
cdk2 from inhibition. The association of p27 with cdk4/6 data).
in proliferating cells ends once TGFb induces a rise in
p15 levels (Figure 5B). Owing to partially overlapping Upstream of cdk Inhibition: Downregulation
binding sites for the two inhibitors and to an equilibrium of c-Myc
of cdk4/6 between a cyclin-bound state in the nucleus c-Myc, a member of the basic helix-loop-helix leucine
and a cyclin-free state in the cytoplasm (Reynisdo´ttir zipper (bHLH-LZ) family of transcription factors, is a
and Massague´, 1997), p27 is displaced by p15 from ubiquitous promoter of cell growth and proliferation
cyclin D-cdk4/6 and shuttled to cyclin E-cdk2, inhibiting (Facchini and Penn, 1998). c-Myc has both transcrip-
this kinase (Reynisdo´ttir et al., 1995; Reynisdo´ttir and tional activation and repression effects depending on
Massague´, 1997; Sandhu et al., 1997). Thus, by increas- the nature of its associated factors (Dang, 1999). As an
ing the level of one single cdk inhibitor, TGFb can inhibit activator, c-Myc, in association with another bHLH-LZ
both classes of G1 cdks. protein, Max, interacts with a consensus sequence
In addition to blocking catalytic activity, binding of termed the E-box in enhancer elements. In various
p27 can occlude a cdk2 complex from phosphorylation TATA-less promoters, c-Myc represses transcription
by cdk-activating kinase (CAK), and this may explain through an interaction with the transcriptional initiator
(Inr) region, a DNA sequence distinct from the E-box.the accumulation of cdk2 lacking this phosphorylation
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In contrast to the cell type–dependent diversity of cdk in others. In fact, apoptosis induced by TGFb family
inhibitory gene responses induced by TGFb, transcrip- members is an essential component of the proper devel-
tional downregulation of c-myc is a rapid and general opment of various tissues and organs, including the
effect observed in most cells with an antiproliferative rhombencephalic neural crest (Graham et al., 1996),
response to TGFb (Alexandrow and Moses, 1995) (Fig- the interdigital fields of the limb (Zou et al., 1997), and
ure 5A). As c-Myc has a short half-life, this down- the mammary gland ductal system (Nguyen and Pollard,
regulation results in a rapid loss of protein. The exact 2000). After lactation, a rise in TGFb3 levels mediates
mechanism of downregulation remains unknown but its the induction of programmed cell death of epithelial cells
importance seems clear: artificially preventing c-Myc that precedes mammary gland involution (Nguyen and
downregulation renders cells resistant to the antiprolif- Pollard, 2000). TGFb-induced apoptosis and the selec-
erative action of TGFb. tive elimination of preneoplastic cells may also be in-
c-Myc downregulation by TGFb is required for the volved in the tumor suppression mediated by TGFb,
TGFb-mediated inactivation of G1 cdks (Warner et al., as a body of largely circumstantial evidence suggests
1999; Claassen and Hann, 2000). A drop in c-Myc protein (reviewed in Gold, 1999). This is especially relevant in
levels in a TGFb-induced response may deprive a cell the case of colon cancer, as colonic epithelial homeosta-
of various functions to which c-Myc contributes in sup- sis is dependent on the rates of both cell proliferation
port of cell proliferation. However, in lung epithelial cells and apoptosis near the tips of villi. Just as loss of TGFb-
conditionally expressing a human c-myc allele, expres- mediated growth arrest might predispose a cell to can-
sion of low levels of exogenous c-Myc blocks the rapid cer, loss of TGFb-mediated apoptosis may permit selec-
transcriptional activation of p15 by TGFb (Warner et al., tive accumulation of premalignant cells. The mechanisms
1999). In keratinocytes, expression of c-myc blocks the that trigger apoptosis in response to TGFb are largely
TGFb induction of p21 (Claassen and Hann, 2000). These unknown, although Bcl family members and caspases
findings suggest that TGFb must downregulate c-Myc that participate in the apoptotic effector system are ac-
in order to activate the p15 and p21 G1 arrest pathways tivated in cells undergoing TGFb-induced apoptosis
(Figure 5A). (Chen and Chang, 1997; Saltzman et al., 1998).
How could c-Myc prevent the induction of cdk inhibi-
tory immediate gene responses by TGFb? c-Myc could TGFb and Cancer
maintain p15 in a basal inhibited state by acting as a Although TGFb is a potent growth inhibitor in epithelial
repressor. In this model, TGFb would have to remove tissues, it is both a suppressor and a promoter of tumori-
this repression in order to proceed with activation of genesis. On the one hand, TGFb has a tumor suppres-
the p15 (and p21) promoter. However, p15 is not induced sion function that is lost in many tumor-derived cell
in epithelial cells whenever the levels of c-Myc decline, lines (Reiss, 1997; reviewed in Gold, 1999). It has been
such as following serum deprivation. In addition to estimated that nearly all pancreatic cancers (Goggins
c-Myc downregulation, other TGFb-dependent signal- et al., 1998; Villanueva et al., 1998) and colon cancers
ing events, perhaps involving Smad proteins, must be (Grady et al., 1999) have mutations disabling a compo-
involved in p15 induction by TGFb. Also of note, c-Myc
nent of the TGFb signaling pathway. Some of these
has been implicated as a positive regulator of cdc25A
mutations occur in the TGFb receptors, Smad4 or
expression (Galaktionov et al., 1996), a mechanism that
Smad2 (see below); others may occur in hitherto un-would also antagonize the effect of TGFb on cdc25A
tested or unknown components of the signaling path-expression (Figure 5A).
way. Experiments in mice have provided additional evi-Resistance to TGFb-mediated growth arrest has been
dence for a role of TGFb in protection against tumorascribed to many other proteins, such as the ras and
progression in the early stages. TGFb1 heterozygousMDM-2 oncoproteins. However, a distinction must be
null mice show increased hepatocyte proliferation, de-made between bona fide members of the TGFb antipro-
creased apoptosis in the lung and liver (Tang et al.,liferative pathway described above and factors which
1998), and accelerated mammary epithelial proliferationsecondarily circumvent TGFb cell cycle arrest signals.
and ductal outgrowth in response to hormone (Bar-For example, hyperactive (oncogenic) Ras, which can
cellos-Hoff and Ewan, 2000). When challenged with car-overcome TGFb-mediated arrest in vivo, has been
cinogens, these mice develop liver and lung tumors ofshown to increase cyclin D levels and increase p27 deg-
greater size, number, and malignant potential than theradation as well as attenuate Smad2/3 nuclear accumu-
controls, suggesting a role for TGFb1 in tumor suppres-lation (Marshall, 1999; Kretzschmar, et al., 1999). While
sion (Tang et al., 1998). These tumors retain the re-these effects would confer TGFb resistance, they do not
maining TGFb1 allele, suggesting haploinsufficiency inplace Ras directly in the TGFb cell-cycle arrest pathway.
the tumor suppressor function of TGFb (Tang et al.,Likewise, while chronic MDM2 overexpression may
1998). Transgenic expression of a dominant-negativeeventually select for cells resistant to TGFb (Sun et al.,
TbRII construct in the mammary gland or the epidermis1998), transient overexpression of MDM2 does not alter
diminishes epithelial responsiveness to TGFb and in-a cell’s sensitivity to TGFb-mediated growth arrest (Blain
creases the tumor incidence in these tissues when theand Massague, 2000), suggesting that, unlike c-Myc,
mice are challenged with a carcinogen (Bottinger et al.,MDM-2 is not a direct participant in the TGFb cell cycle
1997; Go et al., 2000).arrest pathway.
On the other hand, TGFb exacerbates the malignant
phenotype of transformed and tumor-derived cells inTerminal Arrest
experimental systems, and there is some evidence thatIn addition to causing reversible cell cycle arrest in some
cell types, TGFb can induce programmed cell death it may be doing the same in human cancer. High levels of
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TGFb expression are correlated with advanced clinical mutation in one allele may also be accompanied by a
non-BAT-RII mutation that inactivates the kinase do-stage of the tumor (Gold, 1999). Tumor-derived TGFb
could contribute to tumor growth indirectly by sup- main in the other allele (Markowitz et al., 1995; Parsons
et al., 1995; Takenoshita et al., 1997). Recently, missensepressing immune surveillance or stimulating production
of angiogenic factors. However, TGFb can also act di- mutations of TbRII, most of which target the kinase do-
main, have been reported in 15% of microsatellite stablerectly on cancer cells to foster tumorigenesis. Tumor
cells that have selectively lost their growth-inhibitory colon cancers examined (Grady et al., 1999). Thus, inac-
tivating mutations of TbRII may be present in as manyresponsiveness to TGFb but retain an otherwise func-
tional TGFb signaling pathway may exhibit enhanced as one quarter of all colon cancers. Mutational inactiva-
tion of the TGFb type I receptor, or TbRI, has also beenmigration and invasive behavior in response to TGFb
stimulation (Cui et al., 1996; Oft et al., 1998; Yin et al., detected in human cancers. An inactivating mutation in
TbRI occurs in one third of ovarian cancers examined;1999). Expression of dominant-negative TbRII in human
mammary adenocarcinoma cells reduces the size and notably, in the same tumor cohort, no inactivating muta-
tions were identified in TbRII (Wang et al., 2000). A mis-number of bone metastases they generate in athymic
mice (Yin et al., 1999). TGFb signaling could promote sense mutation in the kinase domain of TbRI, resulting
in a hypomorphic allele, has been identified in one cohorttumor cell metastasis in many different ways. Of interest
is the ability of TGFb to induce an epithelial to mesen- of metastatic breast cancers (Chen et al., 1998b) but
not in another (Anbazhagan et al., 1999). In addition,chymal transition (EMT) in these cells (Oft et al., 1998).
EMT is characterized by the downregulation of proteins deletions of TbRI occur at a low frequency in pancreatic
and biliary carcinomas (Goggins et al., 1998) as well asinvolved in cell–cell adhesion and upregulation of mole-
cules important for cell-extracellular matrix associa- cutaneous T cell lymphoma (Schiemann et al., 1999).
Notably, homozygosity of a common germline polymor-tions, ultimately leading to enhanced migratory and in-
vasive properties of the cell. A switch from an epithelial phism, TbRI(6A), is associated with an increased inci-
dence of colon cancer (Pasche et al., 1999).to fibroblastoid phenotype occurs frequently during late
stages of carcinoma progression and correlates with
the metastatic potential of tumor cells. Provocative as Smad Mutations in Cancer
these observations are, an important limitation is that the The TGFb signaling network is also disrupted in cancer
majority of this evidence is derived from experimental by mutations in Smad4 and Smad2. Smad4, initially
metastasis assays that utilize engineered carcinoma cell identified as DPC4 (deleted in pancreatic carcinoma
lines. locus 4) located on 18q21, suffers biallelic loss in one
half of all of pancreatic cancers (Hahn et al., 1996), one
third of metastatic colon tumors (Miyaki et al., 1999),TGFb Receptor Mutations in Cancer
Inactivating mutations in TbRII occur in most human and smaller subsets of other carcinomas. In addition,
germline mutations in Smad4 cosegregate with a sub-colorectal and gastric carcinomas with microsatellite
instability (MSI) (Markowitz et al., 1995). Stable transfec- group of patients with juvenile polyposis syndromes
(JPSs), an autosomal dominant disorder characterizedtion of wild-type TbRII into a human MSI colon cancer
cell line (Wang et al., 1995) and a human gastric cancer by hamartomatous intestinal polyps and an increased
risk of gastrointestinal cancers (Howe et al., 1998). Occa-cell line (Chang et al., 1997) restored TGFb-mediated
growth arrest and reduced tumorigenicity in athymic sionally, Smad4 mutations have been found in conjunc-
tion with TbRI mutations in biliary cancer (Goggins et al.,mice, providing further evidence that mutational inacti-
vation of TGFb receptors is a pathogenic event. MSI is 1998) and with TbRII mutations in colon cancer (Grady et
al., 1999). Smad4 and the TGFb receptors may thereforecommon to many sporadic cancers and results from
DNA mismatch repair (MMR) defects causing nucleotide have certain nonoverlapping tumor suppressive activi-
ties. Smad2, also located on 18q21, is the target ofadditions or deletions in simple repeated sequences, or
microsatellites, throughout the genome. MMR in one inactivating mutations in a small proportion of colorectal
cancers (Eppert et al., 1996; Uchida et al., 1996).such microsatellite, a 10 bp polyadenine repeat within
the TbRII sequence encoding a part of the extracellular Inactivation of Smad2 and Smad4 occurs by loss of
the entire chromosome region, small deletions, frame-domain (referred to as the BAT-RII track), results in a
frameshift and a truncated, inactive TbRII product (Mar- shift, nonsense mutations, or missense mutations. Mis-
sense mutations mostly target the MH2 domain, re-kowitz et al., 1995). BAT-RII inactivating mutations are
also found in colorectal and gastric tumors from patients sulting in loss of stability or disruption of homo- and
hetero-oligomerization of the Smads (Figure 3). Amongwith hereditary nonpolyposis colon cancer (HNPCC), a
familial cancer syndrome in which affected individuals the missense mutations in the MH1 domain, one tar-
geting the same conserved residue in both Smad2 andinherit defects in genes encoding components of the
DNA MMR pathway (Lu et al., 1996; Akiyama et al., 1997). Smad4 results in an enhanced autoinhibitory interaction
between the MH1 and MH2 domains and additionallyAlthough BAT-RII mutations are found in subsets of co-
lon cancers, gastric cancers and gliomas with MSI (Mar- decreases protein stability (Hata et al., 1998; Xu and
Attisano, 2000). Smad-deficient mice display pheno-kowitz et al., 1995; Myeroff et al., 1995; Parsons et al.,
1995; Izumoto et al., 1997), these mutations are uncom- types in support of a tumor suppressor role for the
Smads. Although mice with homozygous loss of Smad2mon in MSI tumors from the endometrium, pancreas,
liver, and breast. Thus, the loss of TbRII is selected for and Smad4 die in utero, their heterozygous counterparts
are viable. In fact, mice heterozygously null for Smad4in only cancers of specific tissue origins.
Most commonly, BAT-RII mutations are biallelic, but develop gastric polyps that can develop into tumors at
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Figure 6. Heritable Mutations in the TGFb
Pathway
Mutations that target components of the
TGFb signaling pathway contribute to diverse
human disorders. The basic signaling com-
ponents are indicated with similar icons as
those depicted in Figure 1. The modes of in-
heritance and the mechanisms of disease are
discussed in the text.
a late age (Xu et al., 2000b). Furthermore, mice defective brosis, hypertension, and osteoporosis. Although ge-
netic alterations in the TGFb system are not known to bein APC (adenomatous polyposis coli ) develop numerous
indolent intestinal polyps. When mice with one mutated a direct cause of these disorders, polymorphisms
in TGFb1 have been associated with ischemic heartAPC allele are crossed with heterozygous null Smad4
mice, the compound heterozygotes develop larger pol- disease and hypertension, osteoporosis, and fibrosis
(Blobe et al., 2000, and references therein).yps that can progress into malignant adenocarcinomas
with loss of the remaining copies of both APC and
Smad4 (Takaku et al., 1998). Moreover, although no noggin Mutations in Hereditary Synostosis
Smad3 mutation has been found in human cancer, mice Endochondral bone development and formation of artic-
with a homozygous deletion of Smad3 develop aggres- ulations between skeletal elements occur simultane-
sive metastatic colorectal cancer at an early age in a ously from the same initial mesenchymal condensation.
manner that seems to be highly dependent on the ge- The BMP-related factor GDF5 (growth and differentia-
netic background of the mice (Zhu et al., 1998). tion factor 5) regulates both the size of the early cartilage
condensation and formation of the joints (Francis-West
et al., 1999; Storm and Kingsley, 1999). Noggin has beenTGFb Signaling Defects in Developmental Disorders
proposed as an upstream modulator of GDF5 signaling,TGFb signaling orchestrates critical roles in mammalian
which is consistent with the similar pattern of jointsembryogenesis and organogenesis (Hogan, 1996; Whit-
affected occurring in humans and mice with either nog-man, 1998; Goumans and Mummery, 2000; Schier and
gin or GDF5 mutations.Shen, 2000; Tremblay et al., 2000). BMP4 acts at distinct
Two autosomal dominant disorders, proximal sym-stages of development, beginning with epiblast prolifer-
phalangism and multiple synostoses syndrome, trace toation and survival preceding gastrulation and later with
heterozygous, missense mutations in noggin, the geneinstructive interactions among many different cell types,
product of which antagonizes BMP/GDF receptor bind-especially neural, cartilage, bone, and dermal cells.
ing (Gong et al., 1999). In proximal symphalangism, syn-Nodal is required for primitive streak formation, anterior
ostosis (osseous union between the bones resulting inpatterning, and the generation of left-right asymmetry
fusion of joints) affects mainly the proximal interphalan-formation. Several other members of the TGFb family,
gial and carpal joints of the hands and tarsal joints ofsuch as Activin, Vg1, BMPs, and Lefty, have also been
the feet. In multiple synostoses syndrome, additionalshown to be important for left-right axis formation. Vari-
sites are involved including the hip and cervical spineous TGFbs are involved in the morphogenesis of many
(Gong et al., 1999). In both disorders, the precise mecha-organs and tissues: TGFb1 in vascular development;
nisms of the missense mutations remain unknown, al-TGFb2 in cardiac, lung, craniofacial, and urogenital de-
though case reports of chromosomal deletions suggestvelopment, and TGFb3 in proper palate closure. Smad
functional haploinsufficiency (Gong et al., 1999). nog-functions are also important during mammalian devel-
gin2/2 mice die at birth from multiple defects includingopment. Smad2-dependent signals generated from the
excessive cartilage and bony fusions of the appendicu-extraembryonic tissues are essential for anterior-poste-
lar skeleton (Brunet et al., 1998; McMahon et al., 1998).rior identity within the underlying epiblast; later, during
Thus, noggin suppresses chondrogensis and joint re-gastrulation, Smad2 signaling directs epiblast deriva-
striction in the limbs of humans and mice.tives toward formation of the definitive endoderm, which
gives rise to the gut tube. Smad4 function is required
for both epiblast proliferation and primitive or extraem- GDF5/CDMP1 Mutations in Hereditary
Chondrodysplasiasbryonic endoderm formation.
Given this, it should come as no surprise that various In the developing limb, early expression of GDF5 is both
necessary and sufficient to stimulate cartilage develop-heritable developmental disorders in humans turn out
to be caused by mutations in the TGFb system (Figure ment and inhibit joint marker expression, including
GDF5 itself and Gli3, thus restricting joint formation later6). In addition, abnormal TGFb signaling has also been
implicated in widespread human disorders including fi- to the appropriate locations. Subsequently, a narrower
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expression of GDF5 in the joint region contributes to joint excluding the carboxy-terminal region. CBFA1 homozy-
gous null mice lack both endochondral and intramem-morphogenesis (Storm and Kingsley, 1999). In addition,
GDF5 accelerates the initial stages of chondrogenesis branous bones, display defects in chondrocyte matura-
tion, and die minutes after birth due to the inability tosuch as mesenchymal condensation by increasing cell
adhesion and later can increase chondrocyte prolifera- breathe. CBFA1 heterozygous null mice show specific
bone defects that phenocopy CCD patients, consistenttion (Francis-West et al., 1999).
Mutations in the human ortholog of GDF5, CDMP1 with CBFA1 haploinsufficiency in the pathogenesis of
CCD (Komori et al., 1997; Otto et al., 1997). Thus, the(cartilage-derived morphogenetic protein 1), are associ-
ated with several human hereditary chondrodysplasias phenotypes of CCD individuals with mutations in CBFA1
and of mice deficient in CBFA1 support an early andincluding Hunter-Thompson type acromesomelic chon-
drodysplasia (Thomas et al., 1996), autosomal dominant critical role of CBFA1 in osteoblast differentiation and
chondrocyte maturation. It will be important to deter-brachydactyly type C (Polinkovsky et al., 1997), and
Grebe type chondrodysplasia (Thomas et al., 1997). mine whether the CCD phenotype of inherited CBFA1
mutations specifically results from a Smad signalingThese are all characterized by pronounced shortening
of the skeletal elements in the limbs, with more severe loss.
effects distally and the loss of one or more joints. The
brachypodism (bp) phenotype in mice is caused by inac- ALK1 and endoglin Mutations in Hereditary
tivating mutations in GDF5 (Storm et al., 1994; Storm Hemorrhagic Telangiectasia
and Kingsley, 1996). Mouse bp sydrome and human Hereditary hemorrhagic telangiectasia (HTT), or Rendu-
Hunter-Thompson type chondrodysplasia are both Osler-Weber syndrome, is inherited as an autosomal
caused by missense mutations in both alleles of GDF5, dominant trait (1 in 10,000) and exhibits age-related pen-
resulting in a total loss of function. Thus, these syn- etrance with variable expressivity (Guttmacher et al.,
dromes are inherited in an autosomal recessive manner. 1995). The earliest and most common clinical manifesta-
In contrast, Grebe type chondrodysplasia and brachy- tions include nosebleeds and mucocutaneous telangi-
dactyly type C follow an autosomal-dominant mode of ectasia; gastrointestinal bleeding usually occurs later in
inheritance. In the former, mutation in a conserved cys- life. Some patients also develop life-threatening compli-
teine (C400Y) of GDF5 yields a dominant negative part- cations involving arteriovenous malformations (AVMs)
ner in the production of dimeric ligand (Thomas et al., in the pulmonary, cerebral, and hepatic circulations. This
1997), which may cause more severe phenotypes than clinical heterogeneity has been explained in part by the
those seen in Hunter-Thomas type chondrodysplasia. identification of two distinct loci, endoglin in HHT1 and
Similarly, brachydactyly type C, which is characterized ALK-1 in HHT2. HHT1 is associated with a higher inci-
by the shortening and the occasional loss of some pha- dence of AVMs than HHT2, which is considered a milder
langes, is due to haploinsufficiency of GDF5 (Polinkov- form with a delayed onset. Moreover, at least one other
sky et al., 1997). gene, still unknown, is involved in the pathogenesis of
HHT (Piantanida et al., 1996).
Both endoglin and ALK-1 are highly expressed onCBFA1 Mutations in Cleidocranial Dysplasia
The core binding factor (CBF) family of transcription endothelial cells and are involved in TGFb superfamily
signaling (Massague´, 1998). ALK-1 is a member of thefactors, which consists of a DNA binding a subunit
(CBFA1, CBFA2, and CBFA3) in association with a com- TGFb type I receptor family, and its physiologic ligand
is unknown. HHT2-associated mutations in ALK-1 aremon b subunit, plays critical roles in tissue growth and
differentiation. CBFA1 (also known as AML3 and PEB- found in the extracellular, transmembrane, and intracel-
lular kinase domain and include frameshift, nonsense,P2aA) functions in bone formation, CBFA2 in hematopoi-
esis, and CBFA3 in B lymphocyte IgA class switching and missense mutations. HHT2 thus appears to result
from a loss-of-function of the mutant (Abdalla et al.,(Westendorf and Hiebert, 1999). Provocative but still ten-
tative evidence suggests that CBFA members may asso- 2000). Endoglin was originally shown to be a nonsignal-
ing ancillary receptor component homologous to beta-ciate with Smads and collaborate in transcriptional acti-
vation of certain TGFb target genes. CBFA1 appears glycan, which enhances TGFb access to the type I and
II receptor complex. However, endoglin shows cross-to show a preference for BMP-activated Smad1, and
CBFA2 and 3 form a functional complex with receptor- reactivity with multiple members of the TGFb superfam-
ily in vitro (Massague´, 1998). The majority of the HHT1-activated Smad3 and 4 to transactivate the germline Iga
constant region (IgCa) (Hanai et al., 1999; Pardali et al., associated mutations in endoglin causes frameshifts
and premature stop codons, and all the missense muta-2000). Both the N-terminal Runt homology DNA binding
domain and the C-terminal transactivation domains of tions identified so far occur in the extracellular domain.
Based on biochemical analyses of these mutants, it ap-CBFA proteins have been implicated in direct CBFA-
Smad interaction. pears that HHT may result from either dominant-nega-
tive protein interactions or haploinsufficiency (Pece-Cleidocranial dysplasia (CCD) is an autosomal-domi-
nant disease characterized by abnormal clavicles, Barbara et al., 1999; Lux et al., 2000). Mice heterozygous
for a null endoglin allele phenocopy human HHT; thosepatent sutures and fontanelles, supernumerary teeth,
short stature, and a variety of other skeletal changes homozygous for a null endoglin allele die in utero at day
10.5 due to angiogenesis defects (Bourdeau et al., 1999).(Mundlos, 1999). Heterozygous mutations in the CBFA1
gene have been identified in CCD patients (Lee et al., While ALK-12/1 mice are normal and fertile, the ALK-12/2
conceptuses also die in utero at day 10.5 due to defects1997; Mundlos et al., 1997). Most CCD-associated muta-
tions are missense and cluster in the Runt domain, not in angiogenesis (Oh et al., 2000).
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The identity of the physiologic ligand for endothelial in embryonic lethality, whereas the heterozygotes are
overtly normal (Beppu et al., 2000). However, mice ho-ALK-1 and endoglin has remained controversial. Al-
though overexpressed ALK-1 can bind TGFb or activin mozygously null for Smad6, an antagonist of the BMP
pathway (Figure 4), display imbalances in cardiovascularwhen coexpressed with the corresponding type II recep-
tors, this binding is much weaker than the binding of homeostasis such as hypertension and a defective nitric
oxide response (Galvin et al., 2000). Thus, BMP signalingthe TGFb type I receptor TbR-I/ALK-5. A constitutively
active form of ALK-1 has been shown to phosphorylate likely plays critical roles in maintaining cardiovascular
homeostasis.and activate Smad1 and 5 but not Smad2 (Macias-Silva
et al., 1998; Chen and Massague´, 1999), suggesting that
ALK-1 mediates BMP-like signaling. Given that the ex- AMH and AMHRII Mutations in Persistent
pression pattern of Smad5 overlaps with those of TGFb1 Mu¨llerian Duct Syndrome
and TbR-II, and that TGFb12/2mice also display vascular In the male fetus, Anti-Mu¨llerian hormone (AMH) (also
defects, it has been proposed that TGFb1 may be a known as Mu¨llerian inhibiting substance, MIS), a rela-
natural ligand for ALK-1 (Oh et al., 2000). However, the tively distant member of the TGFb family, causes the
vascular defects observed in TGFb12/2 conceptuses re- regression of the Mu¨llerian duct, the anlagen of the
sult from alterations in vasculogenesis, not angiogen- uterus, oviducts, and the upper portion of the vagina.
esis, due to inadequate endothelial terminal differen- AMH is produced by the Sertoli cells of the fetal testis
tiation (Dickson et al., 1995). Furthermore, TGFb12/2 and acts on the mesenchymal cells adjacent to the duc-
conceptuses die either at 10.5 dpc due to defects in tal epithelium (Belville et al., 1999). Thus, AMH induces
vasculogenesis (as do TbRII2/2 conceptuses) or later at ductal epithelial regression through a paracrine mecha-
3 weeks post-partum due to severe inflammatory dis- nism originating from the periductal mesenchyme, and
ease (Dickson et al., 1995). The distribution of these both apoptosis and epithelio-mesenchymal transforma-
lethal phenotypes varies with the genetic background tion are involved in AMH-mediated Mu¨llerian duct re-
such that a modifier allele on chromosome 5 of the NIH gression (Allard et al., 2000).
mouse strain can resue TGFb12/2 conceptuses from The critical role of AMH and its type II receptor, AMHR-
lethal vasculogenesis defects. This background, how- II, in mediating sexual dimorphism is demonstrated in
ever, cannot rescue the endoglin null phenotype (Arthur humans by the persistent Mu¨llerian duct syndrome
et al., 2000), suggesting that TGFb1 may not lie in the (PMDS), a rare autosomal recessive disorder character-
same pathway as endoglin in regulating vascular devel- ized by the presence of Mu¨llerian duct derivatives, such
opment. as the uterus and the fallopian tubes, in genetic males
who are otherwise normally virilized (Belville et al., 1999).
About eighty percent of cases are due to inactivatingBMPRII Mutations in Familial Primary
mutations in either AMH or AMHRII. These include mis-Pulmonary Hypertension
sense and nonsense mutations throughout the length ofFamilial primary pulmonary hypertension (PPH) is a rare
the coding regions, insertions, and a common (45% ofautosomal dominant disorder that has reduced pene-
probands) 27 bp deletion in the intracellular domaintrance: inheriting one of at least two genes confers a
of AMHR-II, which is either homozygous or coupled with10%–20% likelihood of developing the disease (Pea-
a missense mutation in the other allele. The etiology ofcock, 1999). This disorder usually affects the arterial side
the remaining twenty percent of PMDS cases remainsof the pulmonary circulation; left untreated, it usually
unknown, although sex-linked inheritance has been re-progresses to severe pulmonary hypertension and right-
ported (Belville et al., 1999). Recent biochemical evi-sided heart failure. With the mean age at onset in the
dence points to BMPR-IB and Smad1 as mediators offourth decade, familial PPH allows a median survival of
AMH and AMHRII (Figure 2), suggesting that AMH gainsonly two years following diagnosis. Recently, familial
access to a shared type I receptor and Smad systemPPH has been shown to be caused by mutations in
through a type II receptor (i.e., AMHR-II) whose tissueBMPRII (Deng et al., 2000; The International PPH Con-
expression pattern is highly restricted (Gouedard et al.,sortium et al., 2000). Nonsense or frameshift mutations
2000). PMDS-associated mutations in BMPR-IB seempredicting premature termination of the receptor in the
unlikely, as PMDS patients do not exhibit any bone andextracellular domain, the transmembrane domain, the
joint abnormality in the appendicular skeleton. The clini-serine/threonine kinase domain, or a carboxy-terminal
cal phenotypes of mutations in either AMH or AMHRIIdomain of unknown biochemical function have been
are the same and are specifically phenocopied in micefound in familial PPH BMPRII alleles. Monoclonality of
with mutations in the corresponding genes. Introductionthe hyperproliferating endothelial cells found in the
of homozygous AMHRII null mutations into female AMHplexiform lesions of familial PPH suggests a need for
transgenic mice rescues all the reproductive abnormali-loss of the remaining wild-type BMPRII allele or a coop-
ties (Mishina et al., 1999), suggesting a high level oferative mutation in a different gene, which may help
specificity between AMH and AMHR-II serving a tempo-explain the low penetrance of familial PPH (Peacock,
rally and spatially restricted role during development.1999).
The histopathologic changes in PPH, including endo-
thelial and smooth muscle cell proliferation and in situ TGIF Mutations in Holoprosencephaly
Signaling defects in ventral forebrain induction underliethrombosis, reflect tissue remodeling in response to
endothelial injury, which may result in an imbalance the developmental anomalies characterizing the herita-
ble human disease holoprosencephaly (HPE; 1 in 250between vasoconstriction and vasodilation (Peacock,
1999). Homozygous disruption of BMPRII in mice results conceptuses and 1 in 10,000 live births), in which the
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forebrain (prosencephalon) fails to cleave into left and etiology of related but more common disorders arising
from somatic mutations in the TGFb pathway. For exam-right hemispheres, telencephalon and diencephalon,
and olfactory and optic bulb tracks (Muenke and ple, the role of BMP signaling in vascular wall homeosta-
sis revealed by the phenotype of BMPRII mutations inBeachy, 2000). In the severest forms, a single brain ven-
tricle is present without evidence of an interhemispheric PPH points to the possibility that other primary forms
of hypertension may arise from somatic alterations offissure, and, in the absence of ventral forebrain struc-
tures, the optic primordia develops as a single evagina- BMP signaling in the vasculature. Conversely, the identi-
fication of somatic mutations in TGFb signaling compo-tion from the floor of the forebrain, resulting in facial
anomalies such as cyclopia (single eye) and displace- nents may facilitate the discovery of heritable forms of
these mutations, as has happened with the identificationment of the nasal structures superiorly. Among at least
twelve chromosomal loci associated with HPE, four HPE of mutations in TBR-II and Smad4 in colon cancer. The
TGFb system may also be perturbed by alterations ingenes have been identified: Sonic Hedgehog (SHH),
ZIC2, SIX3, and TGIF (Muenke and Beachy, 2000). HPE- the embedding network. Think, for example, of the many
forms of cancer in which loss of TGFb responsivenessassociated mutations in the Smad transcriptional core-
pressor TGIF generally involve loss of a single copy of or its degeneration into an instigator of metastasis can-
not be ascribed to a mutation in TGFb receptors orthe TGIF gene or hypomorphic point mutations within
one copy, resulting in only a partial loss of function Smad proteins. Identifying the defect in these cases is
essential and will require a better knowledge of the links(Gripp et al., 2000). Thus, a slight reduction in TGIF levels
can have severe developmental consequences. between TGFb and other signaling pathways.
Signals from the prechordal plate mesoderm and/or
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